Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

We have found a close correlation between viral stavudine (d4T) resistance and resistance to d4T-triphosphate at the human immunodeficiency virus type 1 reverse transcriptase (RT) level. RT from site-directed mutants with 69S-XX codon insertions and/or conventional zidovudine resistance mutations se...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Lennerstrand, J, Stammers, D, Larder, B
Format:	Journal article
Sprache:	English
Veröffentlicht:	2001

Ähnliche Einträge

Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
von: Lennerstrand, J, et al.
Veröffentlicht: (2001)

Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
von: Chamberlain, P, et al.
Veröffentlicht: (2002)

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
von: Harrigan, P, et al.
Veröffentlicht: (2002)

STRUCTURAL STUDIES ON HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE
von: Stammers, D, et al.
Veröffentlicht: (1990)

THE GROWTH AND CHARACTERIZATION OF CRYSTALS OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) REVERSE-TRANSCRIPTASE
von: Jones, E, et al.
Veröffentlicht: (1993)

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
von: Larder, B, et al.
Veröffentlicht: (1999)

Formation of heterodimers of human-immunodeficiency-virus-type-1 reverse transcriptase by recombination of separately purified subunits.
von: Stammers, D, et al.
Veröffentlicht: (1992)

Isolation and characterization of monoclonal antibodies raised against the reverse transcriptase of human immunodeficiency virus type 2 and cross-reactivity with that of type 1.
von: Snowden, W, et al.
Veröffentlicht: (1993)

Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.
von: Debra A Wadford, et al.
Veröffentlicht: (2014-01-01)

Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
von: Auwerx, J, et al.
Veröffentlicht: (2004)

Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance
von: Nicole Bertoletti, et al.
Veröffentlicht: (2020-10-01)

HuR interacts with human immunodeficiency virus type 1 reverse transcriptase, and modulates reverse transcription in infected cells
von: Ennifar Eric, et al.
Veröffentlicht: (2008-06-01)

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
von: Pelemans, H, et al.
Veröffentlicht: (1998)

The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
von: Auwerx, J, et al.
Veröffentlicht: (2004)

Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors.
von: Tisdale, M, et al.
Veröffentlicht: (1989)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
von: Ren, J, et al.
Veröffentlicht: (2008)

HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance.
von: Ren, J, et al.
Veröffentlicht: (2005)

Human Immunodeficiency Virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells
von: Warrilow David, et al.
Veröffentlicht: (2008-12-01)

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
von: Gupta, R, et al.
Veröffentlicht: (2010)

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.
von: Lowe, D, et al.
Veröffentlicht: (1988)

Revealing the Mutation Patterns of Drug-Resistant Reverse Transcriptase Variants of Human Immunodeficiency Virus through Proteochemometric Modeling
von: Jingxuan Qiu, et al.
Veröffentlicht: (2021-09-01)

Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
von: Lucianna Helene Santos, et al.
Veröffentlicht: (2015-11-01)

Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.
von: Conlon, C, et al.
Veröffentlicht: (1994)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
von: Esnouf, R, et al.
Veröffentlicht: (1995)

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.
von: Ren, J, et al.
Veröffentlicht: (1998)

Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
von: Shafer, R, et al.
Veröffentlicht: (1996)

New drug resistance mutations of reverse transcriptase Human immunodeficiency virus type-1 gene in first-line antiretroviral-infected patients in West Sumatra, Indonesia
von: Efrida Efrida, et al.
Veröffentlicht: (2018-05-01)

Anti-feline immunodeficiency virus reverse transcriptase properties of some medicinal and edible mushrooms
von: Supaphorn Seetaha, et al.
Veröffentlicht: (2020-09-01)

The y271 and i274 amino acids in reverse transcriptase of human immunodeficiency virus-1 are critical to protein stability.
von: Hao-Jie Zhang, et al.
Veröffentlicht: (2009-07-01)

Mutations in the Reverse Transcriptase and Protease Genes of Human Immunodeficiency Virus-1 from Antiretroviral Naïve and Treated Pediatric Patients
von: Dinesh Bure, et al.
Veröffentlicht: (2015-02-01)

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
von: Balzarini, J, et al.
Veröffentlicht: (1998)

Click Chemistry-Based Two-Component System for Efficient Inhibition of Human Immunodeficiency Virus (HIV) Reverse Transcriptase (RT)
von: Carlos E. Ledezma, et al.
Veröffentlicht: (2020-02-01)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
von: Ren, J, et al.
Veröffentlicht: (2002)

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
von: Ren, J, et al.
Veröffentlicht: (2004)

Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
von: Ren, J, et al.
Veröffentlicht: (2000)

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
von: Ren, J, et al.
Veröffentlicht: (2006)

Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
von: Smeulders Liesbeth, et al.
Veröffentlicht: (2010-10-01)

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
von: Ren, J, et al.
Veröffentlicht: (2000)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
von: Hopkins, A, et al.
Veröffentlicht: (2004)

HIV REVERSE-TRANSCRIPTASE MUTATION ENABLES EVASION OF CTL MEDIATED IMMUNITY
von: Meier, U, et al.
Veröffentlicht: (1995)